EURASIAN EXPERIMENT JOURNAL OF PUBLIC HEALTH (EEJPH)

ISSN: 2992-4081 ©EEJPH Publications

Volume 7 Issue 1 2025

Impact of Acquired Immunity on Long COVID and Post-Viral Syndromes

Kintuza Lumwako Tebulo and Bamuraza Nfukwe W.

Faculty of Medicine Kampala International University Uganda

ABSTRACT

The emergence of Long COVID and other post-viral syndromes has posed new challenges for healthcare systems worldwide. These conditions, marked by lingering symptoms after the acute phase of infection, affect a significant proportion of individuals following viral infections like SARS-CoV-2, Epstein-Barr virus, and influenza. This review examines the role of acquired immunity in mitigating or influencing the risk, progression, and symptom severity of Long COVID and related syndromes. Adaptive immune responses, such as virus-specific antibodies and T-cell immunity, appear crucial in limiting chronic symptom development, though immune dysregulation may contribute to ongoing symptoms in some cases. We discuss the role of SARS-CoV-2 vaccination in potentially reducing Long COVID incidence by preventing severe initial infections and enhancing viral clearance. Additionally, we explore how cross-immunity from prior viral exposures might affect susceptibility to post-viral syndromes, as well as the role of genetic predispositions and immune dysregulation. Therapeutic implications include the potential for immunomodulatory treatments to manage inflammation and ongoing immune activation in individuals with persistent symptoms. Understanding the interplay between acquired immunity and post-viral syndromes offers insights that may improve prevention and treatment strategies. This review emphasizes the importance of immunity in shaping outcomes of viral infections and suggests pathways for future research and intervention in managing Long COVID and other post-viral syndromes.

Keywords: Long COVID, post-viral syndrome, acquired immunity, adaptive immune response, SARS-CoV-2, vaccination, cross-immunity, immune dysregulation

INTRODUCTION

Long COVID, also known as post-acute sequelae of SARS-CoV-2 infection (PASC), has emerged as a significant public health issue with the potential to affect millions worldwide [1,2]. Characterized by a range of symptoms that persist for weeks, months, or even years after the initial infection, Long COVID can manifest as fatigue, cognitive dysfunction, respiratory issues, and dysautonomia [3,4]. These symptoms often overlap with those observed in other post-viral syndromes, such as myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), which can follow infections from viruses like Epstein-Barr and influenza [5]. Understanding the impact of acquired immunity on Long COVID and post-viral syndromes is crucial, as it may offer insights into symptom progression, prevention, and potential treatment options [6,7].

The immune system's adaptive response plays a critical role in defending against pathogens and can be shaped by factors such as prior infections, vaccination, and genetic predisposition [8]. In the case of SARS-CoV-2, acquired immunity can develop through natural infection or vaccination, resulting in the formation of virus-specific antibodies and T-cell responses that may provide varying degrees of protection against reinfection and severe disease [9]. Notably, acquired immunity appears to influence the likelihood of developing Long COVID; for instance, individuals with stronger initial immune responses and those vaccinated before or after infection often show reduced risk or severity of long-term symptoms [10]. Despite the potential protective role of acquired immunity, immune dys-regulation—often observed in post-viral syndromes—may also contribute to chronic

symptoms [11]. Persistent inflammation, altered cytokine profiles, and the presence of auto-antibodies have been implicated in the pathophysiology of Long COVID, suggesting that the immune system's response to infection may not uniformly prevent or resolve lingering symptoms [12]. This review aims to explore the impact of acquired immunity on Long COVID and other post-viral syndromes by examining mechanisms of adaptive immunity, the role of vaccination, and the influence of cross-immunity from previous viral exposures. Additionally, we consider how genetic predisposition and immune dysregulation may affect symptom persistence and severity. Ultimately, understanding the interplay between acquired immunity and post-viral syndromes could inform vaccination strategies, therapeutic interventions, and research into preventive measures for those at risk of chronic symptoms following viral infections.

Acquired Immunity and Adaptive Response

Mechanisms of Adaptive Immunity

Adaptive immunity, involving B and T lymphocytes, is the immune system's specialized response to specific pathogens, resulting in long-term memory that can respond quickly to subsequent infections [13]. In SARS-CoV-2 infection, adaptive immunity is acquired through natural infection or vaccination, leading to the production of virus-specific antibodies and memory T cells. These immune components provide protection against reinfection and may reduce the severity of future exposures.

Role in Long COVID

Research suggests that adaptive immunity plays a role in determining the risk and severity of Long COVID. Strong initial immune responses, including elevated neutralizing antibodies, are associated with a reduced likelihood of lingering symptoms [14]. However, immune dysregulation—a phenomenon marked by chronic inflammation and altered cytokine production—appears to be a significant factor in those experiencing prolonged symptoms. In some cases, an overly active or misdirected immune response can exacerbate post-viral symptoms rather than resolve them, suggesting that while adaptive immunity may mitigate chronic symptoms for some, it may also contribute to persistent sequelae in others [15]. This highlights the need to better understand how adaptive immunity can be optimized or modulated to prevent and manage Long COVID.

Vaccination and Long COVID

Vaccine-Induced Immunity

SARS-CoV-2 vaccination has proven effective in reducing the severity and mortality associated with acute COVID-19. Recent studies suggest that vaccination may also lower the risk of Long COVID by reducing the likelihood of severe initial infection, which is linked to a higher risk of prolonged symptoms [16]. Vaccination may also help the immune system clear any residual viral particles more effectively, potentially reducing ongoing immune activation that can contribute to chronic symptoms [17]. Additionally, vaccine-induced immune responses could provide more controlled and efficient immune activity, helping to prevent the dysregulated inflammation seen in Long COVID cases.

Timing and Dose Response

The timing and dosage of vaccination appear to influence the risk and progression of Long COVID. Evidence indicates that individuals vaccinated before infection have a reduced likelihood of developing long-term symptoms compared to those who were unvaccinated at the time of infection [18]. Additionally, receiving the vaccine after an initial infection may lessen the severity or duration of persistent symptoms. Some studies suggest that booster doses may further enhance protective effects by reinforcing immune memory and potentially preventing immune exhaustion associated with chronic post-viral symptoms [19]. This highlights the potential role of tailored vaccination strategies in reducing the burden of Long COVID and optimizing immune responses to mitigate post-viral syndromes.

Cross-Immunity and Its Impact on Post-Viral Syndromes

Cross-Immunity Mechanisms

Cross-immunity refers to immune responses to one pathogen providing partial protection against another [20]. In SARS-CoV-2, cross-reactive T-cells from previous exposures to common cold coronaviruses or similar viruses may contribute to reduced severity in initial infections, potentially lowering the risk of developing Long COVID. This cross-reactivity occurs because T-cells recognize certain viral proteins shared across different coronaviruses, allowing the immune system to mount a quicker, more efficient response [21]. Cross-immunity may thus play a role in moderating the immune response to SARS-CoV-2, potentially reducing chronic immune activation that can lead to post-viral symptoms.

Evidence in Post-Viral Syndromes

Cross-immunity may also affect the likelihood and severity of post-viral syndromes linked to other infections, such as Epstein-Barr virus (EBV) and influenza [22]. For example, individuals with pre-existing immunity to similar viral antigens from previous infections may experience modified or dampened immune responses during

subsequent infections, potentially reducing the intensity and duration of post-viral symptoms. However, in cases where cross-reactivity is partial, immune responses may still lead to chronic inflammation or immune dysregulation, contributing to symptom persistence [23]. This complex interaction between pre-existing immunity and immune dysregulation highlights the need for more research on how cross-immunity may help mitigate—or in some cases exacerbate—post-viral syndromes and chronic symptoms, such as those seen in Long COVID.

Immune Dysregulation and Genetic Predisposition

Immune Dysregulation in Long COVID

Persistent immune dysregulation is a key feature of Long COVID and other post-viral syndromes, marked by elevated levels of inflammatory cytokines, autoantibodies, and disrupted T-cell functions [24]. This ongoing immune imbalance may result from incomplete viral clearance or maladaptive immune responses that fail to fully resolve after the initial infection. Such immune dysregulation can drive chronic inflammation and symptom persistence, potentially exacerbating Long COVID outcomes [25].

Genetic and Epigenetic Factors

Genetic predisposition significantly influences the likelihood of developing post-viral syndromes. Certain human leukocyte antigen (HLA) alleles, associated with strong immune responses, may inadvertently heighten the risk of chronic symptoms by contributing to an overly reactive immune state [26]. Epigenetic modifications, which alter gene expression without changing DNA sequences, can also be triggered by viral infections, leading to prolonged immune activation. These genetic and epigenetic factors contribute to individual variability in immune responses, influencing the severity and duration of post-viral symptoms [27]. Understanding these underlying factors can help identify at-risk individuals and pave the way for targeted therapies aimed at managing immune dysregulation in Long COVID and related syndromes.

Therapeutic Implications and Future Directions

Immune Modulation Therapies

Current therapeutic strategies for Long COVID and post-viral syndromes focus on modulating immune responses to reduce chronic inflammation. Treatments targeting cytokine pathways, such as anti-IL-6 agents and JAK inhibitors, are being investigated for their potential to manage excessive immune activation. By addressing specific inflammatory markers, these therapies may help alleviate persistent symptoms linked to immune dysregulation [28].

Role of Antiviral and Immunotherapy

Antiviral therapies aimed at eliminating residual viral particles are also under study to prevent prolonged immune responses [29]. Additionally, immunotherapies that restore immune balance, such as monoclonal antibodies and immune checkpoint inhibitors, show promise in managing immune dysregulation in chronic post-viral syndromes [30]. These treatments aim to reset immune homeostasis, potentially reducing long-term symptoms. Further research is needed to refine these approaches and explore new interventions, such as personalized immunotherapy, which could offer targeted treatment for individuals based on their specific immune profiles [31,32]. Understanding these therapeutic options and their effects on the immune system will be essential for developing effective treatments to improve the quality of life for those affected by Long COVID and similar post-viral conditions [33].

CONCLUSION

The impact of acquired immunity on Long COVID and post-viral syndromes is complex, with both protective and adverse effects depending on individual immune responses. While vaccination appears beneficial in reducing the incidence of Long COVID, immune dysregulation and genetic predisposition contribute to the variability in post-viral sequelae. Future research should focus on characterizing immune response patterns associated with persistent symptoms and developing targeted therapies to modulate immune function in affected individuals.

REFERENCE

1. Wang C, Ramasamy A, Verduzco-Gutierrez M, Brode WM, Melamed E. Acute and post-acute sequelae of SARS-CoV-2 infection: a review of risk factors and social determinants. Virol J. 2023 Jun 16;20(1):124. doi: 10.1186/s12985-023-02061-8. PMID: 37328773; PMCID: PMC10276420.
2. Srikanth Umakanthan, Arun Rabindra Katwaroo, Maryann Bukelo, Shashidhar BG, Prashanth Boralingaiah, Anu V Ranade, Pallavi Rangan, Shabnam Shashidhar, Jyoti Ramanath Kini, Gayathri Kini, Post-Acute Sequelae of Covid-19: A System-wise Approach on the Effects of Long-Covid-19, American Journal of Medicine Open, 2024; 12, 100071. https://doi.org/10.1016/j.ajmo.2024.100071.
3. Daniel O Griffin, Postacute Sequelae of COVID (PASC or Long COVID): An Evidenced-Based Approach, *Open Forum Infectious Diseases*, Volume 11, Issue 9, September 2024, ofae462, https://doi.org/10.1093/ofid/ofae462

4. Lam ICH, Wong CKH, Zhang R, Chui CSL, Lai FTT, Li X, Chan EWY, Luo H, Zhang Q, Man KKC, Cheung BMY, Tang SCW, Lau CS, Wan EYF, Wong ICK. Long-term post-acute sequelae of COVID-19 infection: a retrospective, multi-database cohort study in Hong Kong and the UK. EClinicalMedicine. 2023 Jun;60:102000. doi: 10.1016/j.eclinm.2023.102000. Epub 2023 May 11. PMID: 37197226; PMCID: PMC10173760.
5. Giovanni Furlanis, Alex Buoite Stella, Giovanna Torresin, Marco Michelutti, Miloš Ajčević, Paolo Manganotti, Neurological long-COVID: Associations among fatigue, dysautonomia, depression, and subjective memory complaints, Clinical Neurology and Neurosurgery, 2024; 246, 108522. https://doi.org/10.1016/j.clineuro.2024.108522.
6. Carmona-Torre F, Mínguez-Olaondo A, López-Bravo A, Tijero B, Grozeva V, Walcker M, Azkune-Galparsoro H, López de Munain A, Alcaide AB, Quiroga J, Del Pozo JL, Gómez-Esteban JC. Dysautonomia in COVID-19 Patients: A Narrative Review on Clinical Course, Diagnostic and Therapeutic Strategies. Front Neurol. 2022 May 27;13:886609. doi: 10.3389/fneur.2022.886609. PMID: 35720084; PMCID: PMC9198643.
7. Michael J. Peluso, Steven G. Deeks, Mechanisms of long COVID and the path toward therapeutics, Cell, 2024; 187(20): 5500-5529. https://doi.org/10.1016/j.cell.2024.07.054.
8. Ashmawy R, Hammouda EA, El-Maradny YA, Aboelsaad I, Hussein M, Uversky VN, Redwan EM. Interplay between Comorbidities and Long COVID: Challenges and Multidisciplinary Approaches. *Biomolecules*. 2024; 14(7):835. https://doi.org/10.3390/biom14070835
9. Stefanou M-I, Palaiodimou L, Bakola E, et al. Neurological manifestations of long-COVID syndrome: a narrative review. Therapeutic Advances in Chronic Disease. 2022;13. doi:10.1177/20406223221076890
10. Kervevan J, Staropoli I, Slama D, Jeger-Madiot R, Donnadieu F, Planas D, Pietri MP, Loghmari-Bouchneb W, Alaba Tanah M, Robinot R, Boufassa F, White M, Salmon-Ceron D, Chakrabarti LA. Divergent adaptive immune responses define two types of long COVID. Front Immunol. 2023 Jul 20;14:1221961. doi: 10.3389/fimmu.2023.1221961. PMID: 37559726; PMCID: PMC10408302.
11. Paweł Kozłowski, Aleksandra Leszczyńska, Olga Ciepiela, Long COVID Definition, Symptoms, Risk Factors, Epidemiology and Autoimmunity: A Narrative Review, American Journal of Medicine Open, 2024; 11, 100068.https://doi.org/10.1016/j.ajmo.2024.100068.
12. Davis, H.E., McCorkell, L., Vogel, J.M. *et al.* Long COVID: major findings, mechanisms and recommendations. *Nat Rev Microbiol* **21**, 133–146 (2023). https://doi.org/10.1038/s41579-022-00846-2
13. Netea, M.G., Domínguez-Andrés, J., Barreiro, L.B. *et al.* Defining trained immunity and its role in health and disease. *Nat Rev Immunol* **20**, 375–388 (2020). https://doi.org/10.1038/s41577-020-0285-6
14. Sette A, Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell. 2021 Feb 18;184(4):861-880. doi: 10.1016/j.cell.2021.01.007. Epub 2021 Jan 12. PMID: 33497610; PMCID: PMC7803150.
15. Mohan A, Iyer VA, Kumar D, Batra L, Dahiya P. Navigating the Post-COVID-19 Immunological Era: Understanding Long COVID-19 and Immune Response. *Life*. 2023; 13(11):2121. https://doi.org/10.3390/life13112121
16. Höft, M.A., Burgers, W.A. & Riou, C. The immune response to SARS-CoV-2 in people with HIV. *Cell Mol Immunol* **21**, 184–196 (2024). https://doi.org/10.1038/s41423-023-01087-w
17. Laupèze B, Del Giudice G, Doherty MT, Van der Most R. Vaccination as a preventative measure contributing to immune fitness. NPJ Vaccines. 2021 Jul 27;6(1):93. doi: 10.1038/s41541-021-00354-z. PMID: 34315886; PMCID: PMC8316335.
18. Pollard, A.J., Bijker, E.M. A guide to vaccinology: from basic principles to new developments. *Nat Rev Immunol* **21**, 83–100 (2021). https://doi.org/10.1038/s41577-020-00479-7
19. Zhang, G., Tang, T., Chen, Y. *et al.* mRNA vaccines in disease prevention and treatment. *Sig Transduct Target Ther* **8**, 365 (2023). https://doi.org/10.1038/s41392-023-01579-1
20. Bhattacharyya S, Gesteland PH, Korgenski K, Bjørnstad ON, Adler FR. Cross-immunity between strains explains the dynamical pattern of paramyxoviruses. Proc Natl Acad Sci U S A. 2015 Oct 27;112(43):13396-400. doi: 10.1073/pnas.1516698112. Epub 2015 Oct 12. PMID: 26460003; PMCID: PMC4629340.
21. Fairlie-Clarke KJ, Shuker DM, Graham AL. Why do adaptive immune responses cross-react? Evol Appl. 2009 Feb;2(1):122-31. doi: 10.1111/j.1752-4571.2008.00052.x. Epub 2008 Dec 8. PMID: 25567852; PMCID: PMC3352416.
22. Hu, S., Xiang, D., Zhang, X. *et al.* The mechanisms and cross-protection of trained innate immunity. *Virol J* **19**, 210 (2022). https://doi.org/10.1186/s12985-022-01937-5

23. Ruili Fan, Stefan A.H. Geritz, Evolution of pathogens with cross-immunity in response to healthcare interventions, Journal of Theoretical Biology, 2023; 572, 111575. https://doi.org/10.1016/j.jtbi.2023.111575.
24. Emina Karahmet Sher, Adnan Ćosović, Amina Džidić-Krivić, Esma Karahmet Farhat, Emma Pinjić, Farooq Sher, Covid-19 a triggering factor of autoimmune and multi-inflammatory diseases, Life Sciences, 2023; 319, 121531. https://doi.org/10.1016/j.lfs.2023.121531.
25. Tsilingiris D, Vallianou NG, Karampela I, Christodoulatos GS, Papavasileiou G, Petropoulou D, Magkos F, Dalamaga M. Laboratory Findings and Biomarkers in Long COVID: What Do We Know So Far? Insights into Epidemiology, Pathogenesis, Therapeutic Perspectives and Challenges. *International Journal of Molecular Sciences*. 2023; 24(13):10458. https://doi.org/10.3390/ijms241310458
26. Albright F, Light K, Light A, Bateman L, Cannon-Albright LA. Evidence for a heritable predisposition to Chronic Fatigue Syndrome. BMC Neurol. 2011 May 27;11:62. doi: 10.1186/1471-2377-11-62. PMID: 21619629; PMCID: PMC3128000.
27. Taylor, K., Pearson, M., Das, S. *et al.* Genetic risk factors for severe and fatigue dominant long COVID and commonalities with ME/CFS identified by combinatorial analysis. *J Transl Med* **21**, 775 (2023). https://doi.org/10.1186/s12967-023-04588-4
28. Kenney AD, Dowdle JA, Bozzacco L, McMichael TM, St Gelais C, Panfil AR, Sun Y, Schlesinger LS, Anderson MZ, Green PL, López CB, Rosenberg BR, Wu L, Yount JS. Human Genetic Determinants of Viral Diseases. Annu Rev Genet. 2017 Nov 27;51:241-263. doi: 10.1146/annurev-genet-120116-023425. Epub 2017 Aug 30. PMID: 28853921; PMCID: PMC6038703.
29. Mir I, Aamir S, Shah SRH, Shahid M, Amin I, Afzal S, Nawaz A, Khan MU, Idrees M. Immune-related therapeutics: an update on antiviral drugs and vaccines to tackle the COVID-19 pandemic. Osong Public Health Res Perspect. 2022 Apr;13(2):84-100. doi: 10.24171/j.phrp.2022.0024. Epub 2022 Apr 27. PMID: 35538681; PMCID: PMC9091641.
30. Yang S, Zeng W, Zhang J, Lu F, Chang J, Guo JT. Restoration of a functional antiviral immune response to chronic HBV infection by reducing viral antigen load: if not sufficient, is it necessary? Emerg Microbes Infect. 2021 Dec;10(1):1545-1554. doi: 10.1080/22221751.2021.1952851. PMID: 34227927; PMCID: PMC8354158.
31. Nooraei, S., Bahrulolum, H., Hoseini, Z.S. *et al.* Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers. *J Nanobiotechnol* **19**, 59 (2021). https://doi.org/10.1186/s12951-021-00806-7
32. Bruurs, L.J.M., Müller, M., Schipper, J.G. *et al.* Antiviral responses are shaped by heterogeneity in viral replication dynamics. *Nat Microbiol* **8**, 2115–2129 (2023). https://doi.org/10.1038/s41564-023-01501-z
33. Kálai T, Pongrácz JE, Mátyus P. Recent Advances in Influenza, HIV and SARS-CoV-2 Infection Prevention and Drug Treatment—The Need for Precision Medicine. *Chemistry*. 2022; 4(2):216-258. https://doi.org/10.3390/chemistry4020019

CITE AS: Kintuza Lumwako Tebulo and Bamuraza Nfukwe W. (2025). Impact of Acquired Immunity on Long COVID and Post-Viral Syndromes. EURASIAN EXPERIMENT JOURNAL OF PUBLIC HEALTH, 7(1):61-65